Get the Stockscreener App
0.521
0.78%
-0.0072
Matinas Biopharma Holdings Inc stock is traded at $0.521, with a volume of 16,026.
It is down -0.78% in the last 24 hours and down -13.98% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.5282
Open:
$0.52
24h Volume:
16,026
Relative Volume:
0.04
Market Cap:
$2.65M
Revenue:
-
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.1088
EPS:
-4.79
Net Cash Flow:
$-16.95M
1W Performance:
-5.05%
1M Performance:
-13.98%
6M Performance:
-86.35%
1Y Performance:
+120.12%
1-Day Range:
$0.51
$0.5241
1-Week Range:
$0.5042
$0.58
52-Week Range:
$0.09
$4.49
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.52 | 2.65M | 0 | -21.13M | -16.95M | -4.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
507.87 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
675.50 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
598.61 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.63 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
258.50 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Matinas BioPharma Lands Organovo Chairman, Pharma Veteran in Strategic Board Revamp - StockTitan
Matinas Biopharma Holdings, Inc. to Host Earnings Call - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market SessionArtiva Biotherapeutics (NASDAQ:ARTV) - Benzinga
Matinas Biopharma Announces Agreement For The Acquisition Of Preferred Stock And Appointment Of Dr. Robin L. Smith To The Board Of Directors - Marketscreener.com
Matinas BioPharma Announces Agreement for the Acquisition - GlobeNewswire
Biotech Deal Alert: Matinas BioPharma Lands Critical $3.3M Investment While Strengthening Leadership - StockTitan
Matinas BioPharma announces board member retirement - MSN
Matinas BioPharma announces board member retirement By Investing.com - Investing.com South Africa
Matinas BioPharma Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Matinas Biopharma Appoints Evelyn D’An as Director and Audit Committee Chair - Armenian Reporter
Matinas BioPharma Appoints Evelyn D’An to Board - citybiz
Matinas BioPharma Holdings, Inc. Appoints Evelyn D?An to Board of Directors as an Independent Director and Chair of the Audit Committee - Marketscreener.com
Matinas Biopharma Appoints Evelyn D'An To Board Of Directors As Audit Committee Chair - Marketscreener.com
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair - The Manila Times
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair - GlobeNewswire
Matinas BioPharma announces board member resignation - MSN
Matinas BioPharma announces board member resignation By Investing.com - Investing.com South Africa
Matinas Biopharma Holdings, Inc. Announces Resignation of James S. Scibetta from Board and Audit and Compensation Committees - Marketscreener.com
111 Equity Group Increases Stake In Matinas Biopharma Holdings - citybiz
111 Equity ups stake in Matinas Biopharma Holdings - Investing.com
Activist Investor 111 Equity Takes 5.17% Stake in Matinas BioPharma, Seeks Value Creation - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
**Matinas BioPharma Receives Notice of Noncompliance from NYSE American** - Defense World
Matinas BioPharma Receives NYSE Noncompliance Notice - GlobeNewswire
Matinas BioPharma Receives NYSE American Noncompliance Notice Over Delayed Annual Meeting - StockTitan
State Street Corp Has $54,000 Stock Position in Matinas Biopharma Holdings, Inc. (NYSE:MTNB) - Defense World
MTNB stock touches 52-week low at $0.5 amid sharp annual decline - Investing.com
Matinas Biopharma (NYSE:MTNB) Shares Down 1.3% – What’s Next? - Defense World
Matinas Biopharma Holdings, Inc. Announces Resignation of Kathryn Penkus Corzo from Board, Compensation and Nominating and Corporate Governance Committees - Marketscreener.com
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MTNB (Matinas BioPharma Holdings) EPS (Diluted) : $-4.79 (TTM As of Sep. 2024) - GuruFocus.com
Maxim Group Reiterates Hold Rating for Matinas BioPharma (NYSEAMERICAN:MTNB) - Defense World
MTNBMatinas BioPharma Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Matinas BioPharma plunges as deal for lead asset falls apart - MSN
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through - Pharmaceutical Technology
Matinas BioPharma stock falls on strategic options (MTNB:NYSE) - Seeking Alpha
Nasdaq Down Over 200 Points; Microsoft Shares Fall After Q1 Results - Benzinga
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction - The Manila Times
Matinas BioPharma Announces the Termination of MAT2203 - GlobeNewswire
Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results - Benzinga
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):